New drug targets Cancer's 'Don't eat Me' signal in early trial
NCT ID NCT05378425
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This early-phase study tests a new drug, NTX-1088, which blocks a protein on cancer cells that helps them hide from the immune system. The trial includes about 90 adults with advanced solid tumors that have not responded to standard treatments. Participants receive NTX-1088 alone or with another immunotherapy (pembrolizumab) to see if it is safe and can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Hadassah Medical Center
Jerusalem, 9574425, Israel
-
Maria Skłodowska-Curie National Research Institute of Oncology
Warsaw, Poland
-
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121, United States
-
Sheba Medical Center
Ramat Gan, 5262131, Israel
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.